BioMarin Pharma (BMRN) Announces Enrollment of First BMN 250 Phase 1/2 Patient for MPS IIIB
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has enrolled the first patient in a Phase 1/2 trial for BMN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
